{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:14:39Z","timestamp":1793999679122,"version":"4.8.0"},"reference-count":32,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"\n Importance<\/jats:title>\n Clonal hematopoiesis of indeterminate potential (CHIP) is linked to an increased incidence of cardiovascular and malignant diseases.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine whether CHIP is associated with cardiotoxic effects in patients with breast cancer receiving trastuzumab.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n Analyses of human cohorts with complementary animal experimentation were performed using a nationwide population-based cohort (UK Biobank), 1 tertiary referral center (Seoul National University Hospital [SNUH]), and a controlled laboratory setting. UK Biobank participants were enrolled between 2006 and 2010, and SNUH patients were enrolled from January 2004 to March 2024. Data were analyzed from March 2021 to February 2026.<\/jats:p>\n <\/jats:sec>\n \n Main outcome measures<\/jats:title>\n \n Incident heart failure (HF) in the UK Biobank cohort and trastuzumab-related cardiotoxic effects in the SNUH cohort were the main outcome measures. Trastuzumab-related cardiotoxic effects were defined using established clinical criteria (European Society of Cardiology [ESC], Canadian Trastuzumab Working Group, and Cardiac Review and Evaluation Committee [CREC]). Fine-Gray competing risk models were used to account for death and myocardial infarction; multivariable models were adjusted for age and cardiovascular risk factors in both cohorts, with additional adjustment for anthracycline use in the SNUH cohort. Changes in left ventricular ejection fraction (LVEF) were assessed in\n Tet2<\/jats:italic>\n -deficient bone marrow chimeric mice following trastuzumab exposure.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Overall, 15\u202f729 patients with breast cancer from the UK Biobank cohort (mean [SD] age, 58.8 [7.3] years; 107 [0.68%] male) and 454 female patients with breast cancer who received trastuzumab from the SNUH cohort (mean [SD] age, 52.0 [9.6] years) were included. The corresponding 2-year cumulative incidence values for trastuzumab-related cardiotoxic effects were 15.7% vs 5.0% by ESC criteria (Gray test\n P<\/jats:italic>\n \u2009=\u2009.001), 19.9% vs 10.8% by Canadian criteria (\n P<\/jats:italic>\n \u2009=\u2009.01), and 20.9% vs 11.3% by CREC criteria (\n P<\/jats:italic>\n \u2009=\u2009.02). Using the ESC definition, CHIP positivity (variant allele frequency \u22651.0%) was associated with cardiotoxic effects in multivariable competing risk analysis (adjusted subdistribution hazard ratio, 1.91; 95% CI, 1.32-2.76).\n Tet2<\/jats:italic>\n -deficient mice demonstrated a significant LVEF reduction following trastuzumab treatment (effect size, \u22124.2%; 95% CI, \u22127.91 to \u22120.49;\n P<\/jats:italic>\n \u2009=\u2009.03); other experimental groups showed no significant change.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study, the presence of CHIP was associated with increased susceptibility to trastuzumab-related cardiotoxic effects.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2026.0455","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T15:30:25Z","timestamp":1775143825000},"page":"572","source":"Crossref","is-referenced-by-count":5,"title":["Clonal Hematopoiesis and Risk of Trastuzumab-Related Cardiotoxic Effects"],"prefix":"10.1001","volume":"12","author":[{"given":"Chan Soon","family":"Park","sequence":"first","affiliation":[{"name":"Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gangpyo","family":"Ryu","sequence":"additional","affiliation":[{"name":"Cancer Research Institute, Seoul National University, Seoul, Republic of Korea"},{"name":"Department of Pathology, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo-Jeong","family":"Ahn","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Seoul National University Hospital, Seoul, Republic of Korea"},{"name":"Department of Internal Medicine, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choonghyun","family":"Sun","sequence":"additional","affiliation":[{"name":"NOBO MEDICINE Incorporation, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Pyo","family":"Lee","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Seoul National University Hospital, Seoul, Republic of Korea"},{"name":"Department of Internal Medicine, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung-Kwan","family":"Kim","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Seoul National University Hospital, Seoul, Republic of Korea"},{"name":"Department of Internal Medicine, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Jin","family":"Kim","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Seoul National University Hospital, Seoul, Republic of Korea"},{"name":"Department of Internal Medicine, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sook Young","family":"Jeon","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kangnam Sacred Heart Hospital, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Byoel","family":"Lee","sequence":"additional","affiliation":[{"name":"Cancer Research Institute, Seoul National University, Seoul, Republic of Korea"},{"name":"Department of Surgery, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeong-Gon","family":"Moon","sequence":"additional","affiliation":[{"name":"Cancer Research Institute, Seoul National University, Seoul, Republic of Korea"},{"name":"Department of Surgery, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wonshik","family":"Han","sequence":"additional","affiliation":[{"name":"Cancer Research Institute, Seoul National University, Seoul, Republic of Korea"},{"name":"Department of Surgery, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae-Won","family":"Lee","sequence":"additional","affiliation":[{"name":"Cancer Research Institute, Seoul National University, Seoul, Republic of Korea"},{"name":"Department of Internal Medicine, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Hun","family":"Lee","sequence":"additional","affiliation":[{"name":"Cancer Research Institute, Seoul National University, Seoul, Republic of Korea"},{"name":"Department of Internal Medicine, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sae-Won","family":"Han","sequence":"additional","affiliation":[{"name":"Cancer Research Institute, Seoul National University, Seoul, Republic of Korea"},{"name":"Department of Internal Medicine, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seock-Ah","family":"Im","sequence":"additional","affiliation":[{"name":"Cancer Research Institute, Seoul National University, Seoul, Republic of Korea"},{"name":"Department of Internal Medicine, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Eun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhartha","family":"Jaiswal","sequence":"additional","affiliation":[{"name":"Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California"},{"name":"The Phil & Penny Knight Initiative for Brain Resilience at the Wu Tsai Neurosciences Institute, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngil","family":"Koh","sequence":"additional","affiliation":[{"name":"Cancer Research Institute, Seoul National University, Seoul, Republic of Korea"},{"name":"Department of Internal Medicine, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, Republic of Korea"},{"name":"NOBO MEDICINE Incorporation, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Bean","family":"Park","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Seoul National University Hospital, Seoul, Republic of Korea"},{"name":"Department of Internal Medicine, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"11","key":"coi260010r1","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/S1470-2045(21)00462-9","article-title":"National health system characteristics, breast cancer stage at diagnosis, and breast cancer mortality: a population-based analysis.","volume":"22","author":"Duggan","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"coi260010r3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer.","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"45","key":"coi260010r5","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"issue":"6","key":"coi260010r6","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","article-title":"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.","volume":"18","author":"Di\u00e9ras","year":"2017","journal-title":"Lancet Oncol"},{"issue":"8","key":"coi260010r7","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1001\/jamaoncol.2015.2286","article-title":"The evolving landscape of HER2 targeting in breast cancer.","volume":"1","author":"Moasser","year":"2015","journal-title":"JAMA Oncol"},{"issue":"9","key":"coi260010r8","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1136\/heartjnl-2012-303151","article-title":"Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors.","volume":"99","author":"Farolfi","year":"2013","journal-title":"Heart"},{"issue":"15","key":"coi260010r9","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.008637","article-title":"Trastuzumab in female breast cancer patients with reduced left ventricular ejection fraction.","volume":"7","author":"Nowsheen","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"coi260010r10","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia.","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"24","key":"coi260010r11","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/j.jacc.2012.07.068","article-title":"Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.","volume":"60","author":"Chen","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"coi260010r12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41569-019-0247-5","article-title":"Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease.","volume":"17","author":"Jaiswal","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"10","key":"coi260010r13","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1093\/eurheartj\/ehad869","article-title":"Clonal haematopoiesis of indeterminate potential and atrial fibrillation: an east Asian cohort study.","volume":"45","author":"Ahn","year":"2024","journal-title":"Eur Heart J"},{"issue":"8","key":"coi260010r14","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1093\/eurheartj\/ehz591","article-title":"Clonal haematopoiesis in patients with degenerative aortic valve stenosis undergoing transcatheter aortic valve implantation.","volume":"41","author":"Mas-Peiro","year":"2020","journal-title":"Eur Heart J"},{"issue":"2","key":"coi260010r15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease.","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"issue":"6327","key":"coi260010r16","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1126\/science.aag1381","article-title":"Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice.","volume":"355","author":"Fuster","year":"2017","journal-title":"Science"},{"issue":"3","key":"coi260010r17","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1161\/CIRCRESAHA.118.313225","article-title":"CRISPR-mediated gene editing to assess the roles of Tet2 and Dnmt3a in clonal hematopoiesis and cardiovascular disease.","volume":"123","author":"Sano","year":"2018","journal-title":"Circ Res"},{"issue":"8","key":"coi260010r18","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.jacc.2017.12.037","article-title":"Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1\u00df\/NLRP3 inflammasome.","volume":"71","author":"Sano","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"coi260010r19","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1158\/1078-0432.CCR-22-2598","article-title":"CHIP happens: clonal hematopoiesis of indeterminate potential and its relationship to solid tumors.","volume":"29","author":"Reed","year":"2023","journal-title":"Clin Cancer Res"},{"key":"coi260010r20","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00132","article-title":"Clonal hematopoiesis: updates and implications at the solid tumor-immune interface.","volume":"7","author":"Buttigieg","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"8","key":"coi260010r21","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/s41588-022-01121-z","article-title":"Genome-wide analyses of 200?453 individuals yield new insights into the causes and consequences of clonal hematopoiesis.","volume":"54","author":"Kar","year":"2022","journal-title":"Nat Genet"},{"issue":"4","key":"coi260010r22","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1001\/jamacardio.2019.0302","article-title":"Connections between clonal hematopoiesis, cardiovascular disease, and cancer: a review.","volume":"4","author":"Calvillo-Arg\u00fcelles","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"7","key":"coi260010r23","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1158\/1078-0432.CCR-14-0327","article-title":"DNMT3A mutational status affects the results of dose-escalated induction therapy in acute myelogenous leukemia.","volume":"21","author":"Sehgal","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"12","key":"coi260010r24","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1038\/nm.4210","article-title":"DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.","volume":"22","author":"Guryanova","year":"2016","journal-title":"Nat Med"},{"issue":"1","key":"coi260010r25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jacc.2021.04.085","article-title":"Supplemental association of clonal hematopoiesis with incident heart failure.","volume":"78","author":"Yu","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"coi260010r26","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s40959-025-00386-7","article-title":"Anthracycline- and HER2-induced cardiotoxicity: mechanisms, current strategies, and the emerging role of dapagliflozin as a targeted cardioprotective agent.","volume":"11","author":"Saeed","year":"2025","journal-title":"Cardiooncology"},{"issue":"1","key":"coi260010r27","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jaccao.2022.01.098","article-title":"TET2 clonal hematopoiesis is associated with anthracycline-induced cardiotoxicity in patients with lymphoma.","volume":"4","author":"Hatakeyama","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"10075","key":"coi260010r28","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.","volume":"389","author":"Cameron","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"coi260010r29","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s10549-020-06039-w","article-title":"Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?","volume":"186","author":"Bouwer","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"coi260010r30","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/eurheartj\/ehaa845","article-title":"Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations.","volume":"42","author":"Assmus","year":"2021","journal-title":"Eur Heart J"},{"issue":"19","key":"coi260010r31","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1172\/JCI180066","article-title":"Clonal hematopoiesis and atherosclerosis.","volume":"134","author":"Oren","year":"2024","journal-title":"J Clin Invest"},{"key":"coi260010r32"},{"key":"coi260010r2","unstructured":"International Agency for Research on Cancer. Cancer Today. Accessed October 15, 2025. https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/20-breast-fact-sheet.pdf"},{"key":"coi260010r4","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: female breast cancer. 2021. Accessed October 15, 2025. https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2847154\/jamaoncology_park_2026_oi_260010_1781656679.34931.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:01:06Z","timestamp":1781794866000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2847154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2026.0455","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}